Keros Therapeutics, Inc. (KROS)
After hours:
| Previous close | 49.16 |
| Open | 49.47 |
| Bid | 48.26 x 200 |
| Ask | 48.53 x 100 |
| Day's range | 48.12 - 49.71 |
| 52-week range | 27.02 - 73.00 |
| Volume | |
| Avg. volume | 322,277 |
| Market cap | 1.749B |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.15 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 90.63 |
GlobeNewswireKeros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that five abstracts will be presented from the KER-050 (elritercept) program at the 29th Annual Congress of the Europ
GuruFocus.comKeros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials
Financial Performance Misses Analyst Forecasts Amid Increased R&D Investments
- GlobeNewswire
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended March 31, 2024. “Keros remaine
